We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Clinical Trial to Evaluate the Efficacy and Safety of LEVI-04 in Patients With Osteoarthritis of the Knee

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT05618782
Recruitment Status : Recruiting
First Posted : November 16, 2022
Last Update Posted : November 16, 2022
Sponsor:
Collaborator:
Nordic Bioscience Clinical Development (NBCD)
Information provided by (Responsible Party):
Levicept

Brief Summary:
This is a phase 2, randomized, double-blind, placebo-controlled trial of multiple doses and multiple administrations of LEVI-04 for the treatment of pain due to osteoarthritis of the knee.

Condition or disease Intervention/treatment Phase
Pain Osteo Arthritis Knee Knee Osteoarthritis Arthritis Joint Diseases Musculoskeletal Diseases Rheumatic Diseases Drug: LEVI-04 Other: Placebo: Phase 2

Detailed Description:

The study consists of a Screening Period (including a Diary Run- In/analgesic wash-out Period), Randomization, Post-Randomization Period, and a Follow-up Period. Up to 624 participants will be enrolled and randomized to one of four Treatment Arms at the ratio 1:1:1:1

The overall objective of this study is to evaluate the efficacy and safety of LEVI-04 compared to placebo in patients with knee OA.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 624 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: This is a randomized, double-blind, placebo-controlled trial of multiple doses and multiple administrations of LEVI-04 for the treatment of pain due to osteoarthritis of the knee. The study consists of a Screening Period (including a Diary Run- In/analgesic wash-out Period), Randomization, Post-Randomization Period, and a Follow-up Period. Up to 624 participants will be enrolled and randomized to one of four Treatment Arms at the ratio 1:1:1:1.
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Masking Description: Double- Blind
Primary Purpose: Treatment
Official Title: A Phase 2a, Randomized, Double-Blind, Placebo-Controlled Trial of the Efficacy and Safety of LEVI-04 in Patients With Osteoarthritis of the Knee
Actual Study Start Date : October 17, 2022
Estimated Primary Completion Date : September 13, 2023
Estimated Study Completion Date : December 12, 2023

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Osteoarthritis

Arm Intervention/treatment
Active Comparator: 0.3 mg/kg dose intravenous infusion of LEVI-04
LEVI- 04 is a proprietary p75 neurotrophin receptor fusion protein (p75NTR-Fc).It modulates the nerve growth factor (NGF) pathway, clinically proven to provide effective analgesia.
Drug: LEVI-04
Intravenous infusion

Active Comparator: 1.0 mg/kg dose intravenous infusion of LEVI-04
LEVI- 04 is a proprietary p75 neurotrophin receptor fusion protein (p75NTR-Fc).It modulates the nerve growth factor (NGF) pathway, clinically proven to provide effective analgesia.
Drug: LEVI-04
Intravenous infusion

Active Comparator: 2.0 mg/kg dose intravenous infusion of LEVI-04
LEVI- 04 is a proprietary p75 neurotrophin receptor fusion protein (p75NTR-Fc).It modulates the nerve growth factor (NGF) pathway, clinically proven to provide effective analgesia.
Drug: LEVI-04
Intravenous infusion

Placebo Comparator: Placebo dose intravenous infusion Other: Placebo:
Placebo dose intravenous infusion




Primary Outcome Measures :
  1. To evaluate the efficacy of LEVI-04 (multiple doses) compared to placebo in reducing pain due to knee OA. [ Time Frame: up to 17 weeks ]
    Change in WOMAC pain subscale


Secondary Outcome Measures :
  1. To evaluate the efficacy of LEVI-04 (multiple doses) compared to placebo in improving physical function. [ Time Frame: up to 17 weeks ]
    Change in StEPP

  2. To evaluate the efficacy of LEVI-04 (multiple doses) compared to placebo in improving physical function. [ Time Frame: up to 17 weeks ]
    Change in WOMAC Physical function subscale

  3. To evaluate the efficacy of LEVI-04 (multiple doses) compared to placebo in improving joint stiffness. [ Time Frame: up to 17 weeks ]
    Change in WOMAC Stiffness subscale

  4. To evaluate the efficacy of LEVI-04 (multiple doses) compared to placebo in Patient Global Assessment (PGA). [ Time Frame: up to 17 weeks ]
    Change in PGA

  5. To evaluate rescue medication use in the LEVI-04 group (multiple doses) compared to placebo. [ Time Frame: up to 20 weeks ]
    Rescue Medication usage during the trial

  6. To evaluate the proportion of responders based on various levels of reduced pain in participants receiving LEVI-04 (multiple doses) compared to placebo. [ Time Frame: up to 17 weeks ]
    Change in average weekly NRS score



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   40 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Signed Informed Consent form (ICF).
  2. Male or female participants between ≥40 and ≤80 years of age.
  3. BMI ≤40 kg/m2.
  4. The ability to utilize the eDiary device provided by study sites.
  5. History of knee pain on most days for at least 3 months prior to Screening
  6. Confirmation of OA of the knee

    1. Radiographs of both knees with a Posterior-Anterior, Fixed-flexion view taken during the Screening Period.
    2. American College of Rheumatology (ACR) clinical and radiographic diagnostic criteria.
  7. Evidence of knee OA with a KL grade ≥2, determined through central reading.
  8. Target Knee must have a score of ≥20 out of 50 on the WOMAC pain subscale during Screening and at Randomization
  9. The Baseline (NRS) Pain score will be derived from the last seven days of the Diary Run-In Period and must meet following criteria:

    1. Completion of Average Daily (NRS) Pain score on at least 6 of the 7 days.
    2. Mean Average Daily (NRS) Pain score must be ≥4.0 and ≤9.0
    3. Mean Average Daily (NRS) Pain variability must be ≤1.5
  10. If female, not of childbearing potential defined as post-menopausal for at least 1 year, or surgically sterile (bilateral tubal ligation, bilateral oophorectomy, or hysterectomy), or practicing an agreed upon highly effective method of birth control throughout the study period.
  11. If male and sexually active with partner of childbearing potential, willing to agree to practice a highly effective method of contraception from Visit 2 and at least 3 months after Visit 11 (week 20).
  12. Willing to withdraw from any medication for Osteoarthritis including, but not limited to, Opioids, Non-Steroidal Anti-inflammatories (NSAIDs), COX-2 inhibitors, Topical medication, and Duloxetine.
  13. Participant agrees to take only the allowed Rescue Medications from the start of the Diary Run-In Period through study completion (maximum 4000 mg paracetamol per day).

Exclusion Criteria:

  1. Presence of OA of other major joints (including but not limited to nontarget knee) that could interfere with assessment of pain due to OA of the target knee, in the opinion of the investigator.
  2. Current comorbid condition, other than OA, known to be significantly associated with arthritis or joint pathology, including but not necessarily limited to autoimmune disease with significant joint involvement (e.g., Rheumatoid Arthritis or Paget's disease; Seronegative Spondyloarthropathies (e.g. Ankylosing Spondylitis, Psoriasis arthritis, Reactive arthritis); or other systemic disease involving the target knee (including endocrinopathies).
  3. The following conditions should be excluded: Known presence of rapidly Progressive Osteoarthritis (RPOA), primary osteonecrosis (including spontaneous osteonecrosis of the knee), subchondral insufficiency fractures (SIF), avascular necrosis, osteoporotic fractures, atrophic OA, excessive malalignment of the knee (anatomical axis angle greater than 10 degrees), pathological fractures, or stress fracture or reaction, vertical tear of the posterior meniscal root, or large or extensive subchondral cysts, or target knee anserine or patellar bursitis of clinical relevance
  4. Hip dislocation and congenital hip dysplasia with degenerative joint disease should be excluded.
  5. History of gout with recent (< 6 months) pain flares and uncontrolled uric acid levels. Participants with a history or diagnosis of pseudogout (calcium pyrophosphate dihydrate crystal deposition disease) can enroll if there has not been a flare within 6 months prior to screening and use of NSAIDs is not required for management of this condition.
  6. Presence of neuropathic pain deemed likely to interfere with trial endpoints, complex regional pain syndrome, or chronic widespread pain syndromes e.g., fibromyalgia.
  7. History of significant trauma (e.g., intra-articular fracture) or surgery (excluding injection therapies and arthroscopy) to a knee, hip, or shoulder within the previous 1 year
  8. Planned major surgery or other major invasive procedures while participating in the study.
  9. Surgery or stent placement for coronary artery disease in the six months prior to screening .
  10. Nondiagnostic arthroscopy performed on the target knee joint within 180 days prior to Screening; or diagnostic arthroscopy performed on the target knee joint within 90 days prior to Screening.
  11. Intraarticular injection therapies to the target knee joint within 12 weeks prior to Screening, or to any non-target joint within 6 weeks prior to Screening.
  12. Participants likely to be deemed unfit for joint replacement surgery due to concomitant illness, in the investigator opinion.
  13. Opioid use, including Tramadol, of 4 or more instances per week over the month prior to Screening.
  14. Known history of hypersensitivity to monoclonal antibodies.
  15. Presence of any medical condition or unstable health status that, in the judgment of the investigator, might adversely impact the safety of the participant.
  16. Signs and symptoms of significant cardiac disease, including but not limited to established ischemic heart disease, peripheral arterial disease and /or cerebrovascular disease (unstable angina, myocardial infarction, cardiovascular thrombotic events, transient ischemic attacks, and stroke in the six months prior to screening)
  17. Active malignancy or history of malignancy within the past 5 years, with exception of resected and cured basal cell carcinoma and squamous cell carcinoma of the skin.
  18. Clinically significant abnormal laboratory parameter(s) and/or ECG parameter(s) during Screening, that, in the judgment of the Investigator, would preclude the participant from participation in this study.
  19. Participation in other studies involving investigational drug(s) within 30 days (or 90 days for biologics) prior to screening.
  20. History of Carpal Tunnel Syndrome with symptoms within one year of Screening or a Boston Carpal Tunnel Questionnaire (Symptom Severity Scale) mean score ≥3.
  21. A total Symptom Impact score on the Survey of Autonomic Symptoms ≥3.
  22. Pregnant or breast feeding.
  23. Previously received any form of anti-NGF
  24. Requires walker or wheelchair for mobility (walking stick permitted).
  25. Active or historic substance abuse within one year of Screening in the opinion of the Investigator.
  26. Medical history within 5 years of Screening that involves suicidal ideation, suicide attempt, or increased risk of suicide as assessed by the Investigator.
  27. Presence of any contraindication to MRI

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05618782


Contacts
Layout table for location contacts
Contact: Iwona Bombelka 01304 799760 info@levicept.com
Contact: Claire Herholdt 01304 799760 info@levicept.com

Locations
Layout table for location information
Czechia
CCR Brno, s.r.o Not yet recruiting
Brno, Czechia
Contact: Petra Kopeckova         
CCR Czech a.s Not yet recruiting
Pardubice, Czechia
Contact: Lukas Rocnak         
CCR Prague, s.r.o Not yet recruiting
Prague, Czechia
Contact: Maryna Pesek         
Denmark
Sanos Clinic Nordjylland Not yet recruiting
Gandrup, Denmark
Contact: David Flye Jensen         
Sanos Clinic Herlev Not yet recruiting
Herlev, Denmark
Contact: Christina Kolstrup         
Sanos Clinic Syddanmark Not yet recruiting
Vejle, Denmark
Contact: Anette Rasmussen         
Hong Kong
Hong Kong Center for Clinical Research Recruiting
Hong Kong, Hong Kong
Contact: Ella Chen         
Moldova, Republic of
PMSI Cardiology Institute/RTL SM SRL Consultative ward Not yet recruiting
Chisinau, Moldova, Republic of
Contact: Tatiana Rotaru         
PMSI Clinical Republican Hospital "Timofei Mosneaga" Not yet recruiting
Chisinau, Moldova, Republic of
Contact: Dorian Sasu         
Poland
NZOZ Bif-Med. s.c. Not yet recruiting
Bytom, Poland
Contact: Kamila Stankiewicz         
Medyczne Centrum Hetmańska Not yet recruiting
Poznań, Poland
Contact: Konrad Obst         
Somed CR Not yet recruiting
Warsaw, Poland
Contact: Adrianna Chrominka         
Somed CR Not yet recruiting
Łódź, Poland
Contact: Jakub Kierzkowski         
Sponsors and Collaborators
Levicept
Nordic Bioscience Clinical Development (NBCD)
Investigators
Layout table for investigator information
Study Director: Simon Westbrook Levicept
Layout table for additonal information
Responsible Party: Levicept
ClinicalTrials.gov Identifier: NCT05618782    
Other Study ID Numbers: LEVI-04-21-02
First Posted: November 16, 2022    Key Record Dates
Last Update Posted: November 16, 2022
Last Verified: November 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Levicept:
Osteoarthritis
Knee
Levi-04
Additional relevant MeSH terms:
Layout table for MeSH terms
Arthritis
Osteoarthritis
Osteoarthritis, Knee
Rheumatic Diseases
Joint Diseases
Musculoskeletal Diseases
Collagen Diseases
Connective Tissue Diseases